Summit Financial Wealth Advisors LLC Invests $233,000 in Johnson & Johnson (NYSE:JNJ)
Summit Financial Wealth Advisors LLC Invests $233,000 in Johnson & Johnson (NYSE:JNJ)
Summit Financial Wealth Advisors LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,318 shares of the company's stock, valued at approximately $233,000.
A number of other institutional investors also recently bought and sold shares of the stock. Veracity Capital LLC grew its holdings in shares of Johnson & Johnson by 1.2% during the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company's stock worth $888,000 after buying an additional 59 shares in the last quarter. Sandy Cove Advisors LLC grew its stake in Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company's stock valued at $605,000 after acquiring an additional 60 shares in the last quarter. Paces Ferry Wealth Advisors LLC raised its holdings in Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company's stock valued at $1,425,000 after acquiring an additional 62 shares during the last quarter. Mason & Associates Inc boosted its holdings in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company's stock worth $215,000 after purchasing an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC grew its position in shares of Johnson & Johnson by 0.7% in the third quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company's stock valued at $1,451,000 after purchasing an additional 62 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.
Get Johnson & Johnson alerts:Johnson & Johnson Trading Up 1.0 %
Shares of NYSE JNJ opened at $152.65 on Friday. The stock has a fifty day simple moving average of $159.76 and a 200-day simple moving average of $167.55. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $186.69. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $397.54 billion, a PE ratio of 22.65, a PEG ratio of 2.60 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson's revenue was down 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.13 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson's dividend payout ratio (DPR) is presently 67.06%.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on JNJ. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim assumed coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a "neutral" rating and a $161.00 price objective for the company. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating for the company in a research note on Friday, January 20th. Finally, Atlantic Securities lifted their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a "neutral" rating in a research report on Wednesday, January 25th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $174.73.
Insider Buying and Selling at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.35% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.
See Also
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 10 Best Consumer Discretionary ETFs
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
根據頂峰金融財富顧問有限責任公司向美國證券交易委員會的最新披露,該公司在第四季度收購了強生(紐約證券交易所代碼:JNJ-GET評級)的新股份。該公司收購了1,318股該公司股票,價值約23.3萬美元。
其他一些機構投資者最近也買賣了該股的股票。Veracity Capital LLC在第四季度增持了1.2%的強生股票。Veracity Capital LLC現在持有該公司5,027股股票,價值88.8萬美元,上個季度又購買了59股。Sandy Cove Advisors LLC在第三季度增持了強生1.6%的股份。Sandy Cove Advisors LLC現在擁有3703股該公司股票,價值60.5萬美元,上個季度又收購了60股。Pes Ferry Wealth Advisors LLC在第三季度增持強生股份0.7%。Pes Ferry Wealth Advisors LLC現在擁有8724股該公司的股票,價值1,425,000美元,在上個季度又購買了62股。梅森聯合公司在第三季度增持了4.9%的強生股票。Mason&Associates Inc.在上個季度額外購買了62股後,現在擁有1,317股該公司股票,價值21.5萬美元。最後,白玉蘭資本顧問有限責任公司在第三季度增加了對強生股票的持倉0.7%。Magnolia Capital Advisors LLC現在擁有8,883股該公司股票,價值1,451,000美元,此前該公司在上個季度又購買了62股。67.94%的股票目前由機構投資者和對沖基金持有。
到達強生警報:強生股價上漲1.0%
上週五,紐約證交所JNJ的股價開盤報152.65美元。該股的50日簡單移動均線切入位為159.76美元,200日簡單移動均線切入位為167.55美元。強生的12個月低點為150.11美元,12個月高位為186.69美元。該公司的流動比率為0.99,速動比率為0.77,債務權益比率為0.35。該股市值3,975.4億美元,本益比22.65倍,聚乙二醇率2.60倍,貝塔係數0.54。
強生(紐約證券交易所代碼:JNJ-GET Rating)最近一次發佈收益報告是在1月24日(星期二)。該公司公佈本季度每股收益為2.35美元,比普遍預期的2.22美元高出0.13美元。該公司本季度營收為237.1億美元,而市場普遍預期為239億美元。強生的股本回報率為35.76%,淨利潤率為18.90%。與去年同期相比,強生的收入下降了4.4%。去年同期,該公司公佈的每股收益為2.13美元。股票分析師平均預測,強生本年度每股收益將達到10.5歐元。
強生宣佈分紅
該公司最近還宣佈了季度股息,股息於3月7日(星期二)支付。2月21日(星期二)登記在冊的股東獲得了每股1.13美元的股息。除息日期是2月17日星期五。這意味著年化股息為4.52美元,收益率為2.96%。強生目前的股息支付率為67.06%。
華爾街分析師預測經濟增長
一些研究公司已經加入了對JNJ的看法。2月1日,週三,康託·菲茨傑拉德在一份研究報告中再次發佈了增持評級,並為強生的股票設定了215.00美元的目標價。古根海姆在2月28日星期二的一份報告中對強生的股票進行了報道。他們對該公司的評級為“中性”,目標價為161.00美元。派珀·桑德勒在2月6日週一的一份研究報告中將強生的目標價從55美元下調至52美元。1月20日,SVB Leerink在一份研究報告中將強生的目標股價從194.00美元下調至186.00美元,並將該公司的評級定為“跑贏大盤”。最後,大西洋證券將強生股票的目標價從160.00美元上調至168.00美元,並在1月25日(週三)的一份研究報告中給予該公司“中性”評級。7名研究分析師對該股的評級為持有,6名分析師給出了買入評級,一名分析師給出了強烈的買入評級。根據MarketBeat.com的數據,該公司的平均評級為“適度買入”,共識目標價為174.73美元。
強生的內幕買賣
在其他新聞方面,內部人士詹姆斯·D·斯旺森在3月6日星期一的一次交易中出售了1062股該公司股票。這只股票的平均售價為154.66美元,總價值為164,248.92美元。出售後,這位內部人士現在直接擁有該公司9,215股,價值1,425,191.90美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可以通過此超鏈接。公司內部人士目前持有該公司0.35%的股份。
強生簡介
(獲取評級)
強生是一家控股公司,從事醫療保健領域產品的研發、製造和銷售。它通過以下部門運營:消費者健康、製藥和MedTech。消費者健康部分包括專注於個人保健的產品,用於皮膚保健/美容、非處方藥、嬰兒護理、口腔護理、婦女健康和傷口護理市場。
另請參閱
- 免費獲取斯托克新聞網關於強生(JNJ)的研究報告
- 市場回顧周-3/20-3/24
- 紅利王正品配件公司利潤指引升級
- 埃森哲的底部已經到了
- 2023年11只最佳非必需消費品股票
- 十大最佳消費者可自由支配ETF
想看看其他對沖基金持有JNJ的是什麼嗎?訪問HoldingsChannel.com獲取強生(紐約證券交易所代碼:JNJ-GET Rating)的最新13F檔案和內幕交易資訊。
接受《強生日報》的新聞和評級-在下面輸入您的電子郵件地址,即可通過MarketBeat.com的免費每日電子郵件時事通訊接收對強生及相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧